Dynavax Technologies CorpChange company Symbol lookupSelect an option...DVAX Dynavax Technologies CorpSPRC Scisparc LtdNRSN Neurosense Therapeutics LtdACNT Ascent Industries CoFATH Fathom Digital Manufacturing CorpPAYX Paychex IncWAVD Wavedancer IncRNXT RenovoRx IncGBNY Generations Bancorp NY IncPOL Polished.Com IncGo
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B vaccine and CpG 1018. Its HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. It is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, which are focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza, and universal influenza.
|
|
|
|
| |
Company Profile
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B vaccine and CpG 1018. Its HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. It is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, which are focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza, and universal influenza.
Valuation Ratios
- Price/Earnings (TTM)
- 21.16x
- Price/Sales (TTM)
- 4.14x
- Price/Book (MRQ)
- 3.29x
- Price/Cash Flow (TTM)
- 16.61x
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in thousands.
Company Officers
- Scott D. Myers
- David F. NovackPres.
- Ryan SpencerCEO
- Kelly MacDonaldCFO
- Robert JanssenSr.VP
Address
- 2100 Powell Street, Suite 720
- Emeryville, CA 94608
- Phone: (510) 848-5100
- Fax: (510) 848-1327
- https://www.dynavax.com/
Insider Trading
During the most recent quarter, 3M shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.